Life Sciences Update - April 2017

At a time of extreme financial pressure on the health service, the tension between providing medicines at an affordable cost and the need to fund the development of innovative and increasingly sophisticated medicines is particularly acute. In a series of notes we look at the current state of pharmaceutical pricing regulation in the UK and consider changes on the horizon. Read more

The new EU Medical Device Regulation and the EU In vitro Diagnostics Regulation were adopted by the European Parliament on 6 April and are set to be published in the Official Journal in May. We provide a brief update on the main changes.  

Filing for patents is often a key ingredient in securing the finance to develop and test new drug candidates. Charlotte Tillett (Partner and Head of our Life Sciences group) and Andrew Dodds (Senior Banking and Finance Associate) consider the implications of the Unified Patent Court for finance transactions.

EU Pharmaceutical Law Forum, 16-18 May - Members of our Life Sciences team will be attending the EU Pharmaceutical Law Forum in Brussels as one of the conference sponsors.

INTA, 20-24 May - Members of our Life Sciences team will be attending INTA in Barcelona.

We look forward to catching up with many of you at these events. Please get in touch if you would like to arrange a meeting.

For further information about our Life Sciences practice, please contact Charlotte Tillett, Head of Life Sciences at Stevens & Bolton LLP, on 01483 406956 or email charlotte.tillett@stevens-bolton.com